Quality of life after treatment with immune checkpoint inhibitors for lung cancer; the impact of age
Author:
Funder
Horizon 2020 Framework Programme
Horizon 2020
Consejo Nacional de Ciencia y Tecnología
Publisher
Elsevier BV
Subject
Cancer Research,Pulmonary and Respiratory Medicine,Oncology
Reference38 articles.
1. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries;Bray;CA. Cancer J. Clin.,2018
2. Immunotherapy in Lung Cancer: A New Age in Cancer Treatment;Corrales,2018
3. Review and perspective on adjuvant and neoadjuvant immunotherapies in NSCLC;Yi;Oncol. Targets Ther.,2019
4. Systemic therapy for locally advanced and metastatic non-small cell lung cancer: a review;Arbour;JAMA - J. Am. Med. Assoc.,2019
5. The impact of symptoms, coping capacity, and social support on quality of life experience over time in patients with lung cancer;Henoch;J. Pain Symptom Manage.,2007
Cited by 3 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Changes in Global Quality of Life after treatment with immune checkpoint inhibitors in patients with advanced stage lung cancer in the Netherlands – a 2015-2021 cohort study;2024-04-30
2. Health-related quality of life and its influencing factors among lung cancer patients receiving immune checkpoint inhibitors: A cross-sectional study;European Journal of Oncology Nursing;2024-02
3. PD-1/PD-L1 Inhibitors for the Treatment of Lung Cancer;Immunotherapy Against Lung Cancer;2024
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3